This research investigates the role of oligodendrocytes in Fragile X syndrome, revealing delayed cell maturation and disrupted myelin development. Using human stem cell and mouse models, it identifies these overlooked cells as promising therapeutic targets, potentially enabling earlier and more effective treatments for Fragile X and related neurodevelopmental disorders.

This research shows that early-life oxytocin treatment can reverse key features of fragile X syndrome in mice. Brief intervention strengthens neural connections, normalizes learning and social behavior, and prevents seizures into adulthood. The findings suggest oxytocin may offer a safe, early intervention strategy for fragile X and other intellectual disabilities.